Michael Feld Sells 75 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of the firm’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $157.13, for a total value of $11,784.75. Following the completion of the transaction, the executive vice president directly owned 20,934 shares in the company, valued at $3,289,359.42. This trade represents a 0.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Friday, June 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $152.80, for a total value of $11,460.00.
• On Tuesday, May 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $147.35, for a total value of $11,051.25.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX opened at $168.56 on Thursday. The business’s 50-day simple moving average is $151.10 and its 200 day simple moving average is $163.89. The company has a market cap of $46.44 billion, a P/E ratio of 42.67, a PEG ratio of 11.77 and a beta of 0.21. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. Becton, Dickinson and Company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the company earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 12.62 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.5%. Becton, Dickinson and Company’s payout ratio is 106.33%.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: UBS initiated coverage with a Buy rating and a $190 price target, implying meaningful upside from recent trading levels. The upgrade may be the biggest near-term catalyst, signaling that UBS sees improving risk-reward prospects for BD. UBS initiates coverage of Becton Dickinson
• Positive Sentiment: BD and Brazilian pharmaceutical company EMS launched a semaglutide product in Brazil, combining EMS’s pharmaceutical capabilities with BD’s advanced drug-delivery technology. The partnership could expand access to GLP-1 therapies and create potential demand for BD’s injection and delivery systems. EMS and BD semaglutide launch
• Neutral Sentiment: BD declared a quarterly dividend of $1.05 per share, payable September 30 to shareholders of record September 9. The announcement supports the company’s shareholder-return profile, although the dividend was expected and is unlikely to materially change earnings expectations. BD dividend announcement
• Negative Sentiment: Executive Vice President Michael Feld sold 75 shares worth approximately $11,785 under a pre-arranged Rule 10b5-1 trading plan. Because the sale reduced his holdings by only 0.36% and was scheduled in advance, it represents a limited negative signal rather than a major change in insider sentiment. BDX insider stock sale

Analysts Set New Price Targets

Several analysts have recently weighed in on BDX shares. Stifel Nicolaus lowered their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. TD Cowen lowered their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research note on Monday, May 4th. The Goldman Sachs Group dropped their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Finally, Piper Sandler cut their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $180.93.

Hedge Funds Weigh In On Becton, Dickinson and Company

Several institutional investors have recently made changes to their positions in BDX. Auto Owners Insurance Co raised its position in shares of Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after purchasing an additional 40,528,680 shares during the period. Vanguard Group Inc. boosted its position in Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after purchasing an additional 4,223,149 shares during the period. State Street Corp grew its stake in Becton, Dickinson and Company by 0.8% during the 4th quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock worth $2,714,871,000 after buying an additional 116,737 shares during the last quarter. First Eagle Investment Management LLC grew its stake in Becton, Dickinson and Company by 16.5% during the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock worth $2,260,139,000 after buying an additional 1,651,592 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in Becton, Dickinson and Company by 3.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier’s stock worth $1,841,083,000 after buying an additional 336,110 shares during the period. 86.97% of the stock is owned by institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.